Voyager Therapeutics, Inc. (VYGR)
VYGR moved a median of -0.12% 30 minutes after news, and -0.15% by the close. How VYGR actually reacts to news — the realized, point-in-time move the market made, measured across 320 labeled events over the last three years with zero look-ahead.
VYGR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 47% | 319 |
| 30-min | -0.12% | 42% | 320 |
| 60-min | 0.00% | 46% | 320 |
| to close | -0.15% | 48% | 320 |
| Middle 50% of VYGR reactions | -1.54% to +0.94% |
|---|---|
| Median reaction (30-min) | -0.12% |
| Measured reactions | 320 |
Half of all Voyager Therapeutics, Inc. news events land between -1.54% and +0.94% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How VYGR reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 12 | -0.36% | 50% | -1.61% |
| Coverage initiations | 18 | +2.27% | 61% | +1.31% |
| Rating reiterations | 44 | -0.09% | 43% | +0.37% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how VYGR ranks against every other measured name →
That’s how VYGR usually reacts — get an email when it moves on news →Email me when VYGR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to VYGR's baseline. Nothing else.
Recent VYGR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Voyager to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +0.44% | +0.29% | |
| Form 10-Q Voyager Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.47% | +6.51% | |
| Form 8-K Voyager Therapeutics, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +1.47% | +6.51% | |
| Voyager Reports Second Quarter 2026 Financial and Operating Results | Press release | GlobeNewswire | +1.47% | +6.51% | |
| Form 8-K Voyager Therapeutics, For: Jul 13 | SEC filing · Form 8-K | SEC EDGAR | -2.94% | -4.71% | |
| Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026 | Press release | GlobeNewswire | -2.94% | -4.71% | |
| Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026 | Press release | GlobeNewswire | +2.25% | +0.84% | |
| Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference | Press release | GlobeNewswire | +1.02% | +2.04% | |
| Form 8-K Voyager Therapeutics, For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | -1.81% | +4.22% | |
| Form 8-K Voyager Therapeutics, For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | -1.50% | -2.32% | |
| Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease | Press release | GlobeNewswire | -1.50% | -2.32% | |
| Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026 | Press release | GlobeNewswire | +1.46% | +0.97% | |
| Form 10-Q Voyager Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +3.32% | |
| Form 8-K Voyager Therapeutics, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.32% | |
| Voyager Reports First Quarter 2026 Financial and Operating Results | Press release | GlobeNewswire | +0.00% | +3.32% | |
| Form ARS Voyager Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.47% | -2.93% | |
| Form DEF 14A Voyager Therapeutics, For: Jun 09 | SEC filing · Form DEF | SEC EDGAR | -1.47% | -2.93% | |
| Form DEFA14A Voyager Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -1.47% | -2.93% | |
| Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease | Press release | GlobeNewswire | +1.07% | +0.53% | |
| Form 8-K Voyager Therapeutics, For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | +1.87% | +3.24% | |
| Form PRE 14A Voyager Therapeutics, For: Jun 09 | SEC filing · Form PRE | SEC EDGAR | +2.93% | +2.13% | |
| Form 10-K Voyager Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +21.66% | |
| Form 8-K Voyager Therapeutics, For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +21.66% | |
| Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results | Press release | GlobeNewswire | +0.00% | +21.66% | |
| Form 8-K Voyager Therapeutics, For: Feb 09 | SEC filing · Form 8-K | SEC EDGAR | +1.52% | -5.53% | |
| Voyager to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | -0.82% | +1.37% | |
| Form 8-K Voyager Therapeutics, For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | -0.12% | +0.74% | |
| Form EFFECT Voyager Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -0.76% | -4.32% | |
| Form 10-Q Voyager Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.42% | +0.71% | |
| Form 8-K Voyager Therapeutics, For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +1.42% | +0.71% | |
| Form S-3 Voyager Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | -2.82% | +0.23% | |
| Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia | Press release | GlobeNewswire | +1.42% | +0.71% | |
| Voyager Reports Third Quarter 2025 Financial and Operating Results | Press release | GlobeNewswire | +1.42% | +0.71% | |
| Form 8-K Voyager Therapeutics, For: Sep 02 | SEC filing · Form 8-K | SEC EDGAR | -0.34% | +7.19% | |
| Voyager to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +0.26% | +1.48% | |
| Form 10-Q Voyager Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.72% | -5.29% | |
| Form 8-K Voyager Therapeutics, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.72% | -5.29% | |
| Voyager Reports Second Quarter 2025 Financial and Operating Results | Press release | GlobeNewswire | +0.72% | -5.29% | |
| Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach | Press release | GlobeNewswire | +0.95% | +3.81% | |
| Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference | Press release | GlobeNewswire | +1.34% | +2.98% | |
| Form S-8 Voyager Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +1.34% | +2.98% | |
| Form 8-K Voyager Therapeutics, For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +0.60% | +6.63% | |
| Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication | Press release | GlobeNewswire | -0.63% | +3.47% | |
| Form 10-Q Voyager Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.93% | +1.24% | |
| Form 8-K Voyager Therapeutics, For: May 06 | SEC filing · Form 8-K | SEC EDGAR | +0.93% | +1.24% | |
| Voyager Reports First Quarter 2025 Financial and Operating Results | Press release | GlobeNewswire | +0.93% | +1.24% | |
| Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting | Press release | GlobeNewswire | -1.24% | +1.56% | |
| Form ARS Voyager Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.14% | +1.15% | |
| Form DEF 14A Voyager Therapeutics, For: Jun 03 | SEC filing · Form DEF | SEC EDGAR | -0.14% | +1.15% | |
| Form DEFA14A Voyager Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -0.14% | +1.15% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the VYGR section they belong to.
Where else VYGR is measured.
VYGR earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | 321 | -0.14% | 45% |
| Pulse Biosciences, Inc (PLSE) | 320 | +0.18% | 55% |
| Viking Therapeutics, Inc. (VKTX) | 319 | -0.60% | 43% |
| Aptevo Therapeutics Inc. (APVO) | 318 | -0.89% | 34% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Voyager Therapeutics, Inc.'s median reaction calculated?
Every labeled VYGR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 320 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of VYGR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does VYGR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.